Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of microformulation over conventional eyedroppers and addition of scientific advisory board members
Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure through Eyenovia’s ophthalmic microformulation
Prof. Robert N. Weinreb, Director, Shiley Eye Institute and Chair, Department of Ophthalmology, University of California San Diego and Prof. Louis Pasquale Director, Glaucoma Service, Massachusetts Eye and Ear and Professor of Ophthalmology, Harvard Medical School are joining Eyenovia’s scientific advisory board
Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class micro-therapeutics for the eye announces the publication of Phase II results in the peer-review journal “Therapeutic Delivery”. The Phase II randomized controlled clinical study was conducted in more than 100 subjects who received high-precision microformulation of 6µL of a dilatory agent versus standard eye dropper dosing of 40-50µL to compare the pharmacodynamic outcome of pupillary dilation measured by digital pupilometry. The results show that Eyenovia’s micro-formulation achieved either equivalent or greater biologic effect compared to standard eye drop therapy. Separately, participants preferred Eyenovia’s high-precision microdose to eyedroppers, reporting better head-positioning comfort, reduced tearing/overflow and increased likelihood of adhering to ocular medication regimens.
“Ophthalmic micro-formulation has been one of the lasting barriers to the development of innovative and safer topical treatments in the field of ophthalmology. Conventional eyedroppers, which have been used for over 100 years, overdose by a factor of 7-8 times the volume of the tear film – this overexposure is the reason many drugs continue to cause redness, itching, irritation and even systemic side effects such as fatigue, shortness of breath and blood pressure fluctuations. Microdose can usher a new therapeutic paradigm” said Dr. Weinreb, Chairman of the Department of Ophthalmology, University of California, San Diego.
“We are very excited at the disruptive potential of our technology which can greatly improve the therapeutic profile of many existing and new treatments. High precision micro-formulation for ocular surface printing of drugs brings advances from inkjet printer technology which can transform how we treat patients with eye problems. With the addition of smart monitoring functions for compliance tracking and enhancement, Eyenovia will complement its pipeline of microtherapeutics with a digital health platform for smarter eye care” said Dr. Ianchulev, Eyenovia’s CEO.
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases. For more information, visit www.eyenoviabio.com.